Tatro Capital LLC bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,022 shares of the company’s stock, valued at approximately $298,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. Pendal Group Limited purchased a new position in Henry Schein in the first quarter valued at about $90,177,000. BlackRock Inc. boosted its stake in Henry Schein by 5.7% in the first quarter. BlackRock Inc. now owns 13,823,416 shares of the company’s stock valued at $957,135,000 after acquiring an additional 740,349 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Henry Schein by 63.3% in the first quarter. D. E. Shaw & Co. Inc. now owns 1,184,325 shares of the company’s stock valued at $82,003,000 after purchasing an additional 459,181 shares during the period. Handelsbanken Fonder AB raised its position in shares of Henry Schein by 452.8% in the second quarter. Handelsbanken Fonder AB now owns 291,548 shares of the company’s stock valued at $21,630,000 after purchasing an additional 238,806 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Henry Schein by 9.0% in the second quarter. American Century Companies Inc. now owns 2,854,454 shares of the company’s stock valued at $211,772,000 after purchasing an additional 235,831 shares during the period. Hedge funds and other institutional investors own 93.16% of the company’s stock.
Shares of NASDAQ HSIC opened at $75.97 on Tuesday. The company has a current ratio of 1.79, a quick ratio of 0.98 and a debt-to-equity ratio of 0.18. Henry Schein, Inc. has a 12 month low of $56.31 and a 12 month high of $83.45. The firm has a market capitalization of $10.61 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. The firm has a fifty day simple moving average of $77.02 and a two-hundred day simple moving average of $74.80.
A number of analysts recently weighed in on HSIC shares. Barrington Research upped their target price on shares of Henry Schein from $91.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, August 4th. Piper Sandler increased their price target on shares of Henry Schein from $89.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, August 3rd. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Henry Schein presently has an average rating of “Buy” and an average price target of $89.25.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Further Reading: The risks of owning bonds
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.